Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 287Observational 11Expanded_access 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 2KRAS G12V Mutant Advanced Epithelial Cancers 1Glioma 1Glioblastoma 1

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1lifileucel 1efineptakin alfa 1balstilimab 1aldesleukin 1Melphalan 1Cyclophosphamide 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × pembrolizumab × Clear all
NCT02083484 2018-01-26

Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)

Merck Sharp & Dohme LLC

No longer available
Dermatologic

Melanoma

NCT03311542 2018-01-10

Expanded Access for Pembrolizumab (MK-3475)

Center Trials & Treatment

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡